Stocks · News reference
LeMaitre Vascular shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 GAAP EPS and FY2026 sales guidance.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 11:41 AM
- Checked
- Aug 5, 2026, 11:41 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — LEMAITRE VASCULAR INC (LMAT)
Filed: 2026-08-04 AccNo: 0001193125-26-332982 Size: 383 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarLeMaitre Vascular Sees Q4 GAAP EPS $0.75-$0.81 vs $0.78 Est; Sees Sales $71.100M-$73.100M vs $72.745M Est
LeMaitre Vascular (NASDAQ:LMAT) is looking for Q4 GAAP EPS of $0.75-$0.81 vs $0.78 analyst estimate. sees sales of $71.100 million-$73.100 million vs $72.745 million analyst estimate.
Read original at benzinga